• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » GE posts mixed-bag Q3 results as GE HealthCare spinoff remains on track

GE posts mixed-bag Q3 results as GE HealthCare spinoff remains on track

October 25, 2022 By Danielle Kirsh

GE HealthCare's new logoGE (NYSE: GE) this week posted third-quarter results that beat the revenue consensus on Wall Street but missed on earnings.

GE HealthCare spinoff plans remain on track for an early January 2023 completion.

The Boston-based company reported a loss of -21¢ per share for the three months ended Sept. 30, 2022, versus a profit of $1.08 during Q3 2021. Sales were up 2.8% year-over-year to nearly $19.1 billion.

Adjusted to exclude one-time items, earnings per share were 35¢, 11¢ behind The Street, where analysts were looking for sales of $18.6 billion.

GE HealthCare reported $4.6 billion in sales, a 6.3% gain from Q3 2021. Net profits came in at $712 million, representing a 1.1% gain year-over-year.

“Our planned spin-offs remain on track with GE HealthCare ready to go in the first week of January. With leading positions in growing, critical sectors, we are excited about our plans to launch three independent, investment-grade companies set up to create long-term shareholder value,” CEO Lawrence Culp said in a news release.

Shares in GE were down more than 2% to $71.65 apiece in morning trading. MassDevice‘s MedTech 100 Index, which includes stocks of the world’s largest medical device companies, was up more than 2%.

More on GE HealthCare and the Q3 earnings report

Sales at GE HealthCare were primarily driven by its Imaging and Ultrasound businesses. The company continues to expect mid-single digit revenue growth while operating profit is anticipated to be at least $2.6 billion but may be impacted by inflation, foreign exchange and investments.

GE HealthCare achieved critical milestones in Q3 for its planned spinoff in January 2023, including naming a board of directors and filing its Form 10 registration statement. Financially, the company continued to deliver precision health innovation throughout the quarter. It expanded its partnership with AliveCor and announced a collaboration with AMC Health to enable remote patient monitoring.

GE is maintaining its prior organic revenue outlook for 2022, predicting that it will trend toward the low end of the high-single-digit growth range. The company projects adjusted earnings per share in the range of $2.40 to $2.80. Wall Street analysts, on average, expect adjusted EPS of $2.63 this year.

Filed Under: Business/Financial News, Featured, MassDevice Earnings Roundup, News Well, Wall Street Beat Tagged With: GE, GE Healthcare

More recent news

  • Breaking: Sequel to launch twiist automated insulin delivery system next month
  • Dexcom shares U.S. report on CGM benefits for type 2 diabetes
  • Data backs Medtronic MiniMed 780G for type 2, children as company seeks expanded indications
  • Endogenex data supports type 2 diabetes procedure
  • Ambu wins FDA clearance for first single-use cysto-nephroscope

About Danielle Kirsh

Danielle Kirsh is an award-winning journalist and senior editor for Medical Design & Outsourcing, MassDevice, and Medical Tubing + Extrusion, and the founder of Women in Medtech and lead editor for Big 100. She received her bachelor's degree in broadcast journalism and mass communication from Norfolk State University and is pursuing her master's in global strategic communications at the University of Florida. You can connect with her on Twitter and LinkedIn, or email her at [email protected].

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy